Small-Molecule Inhibitors of the ERK Signaling Pathway: Towards Novel Anticancer Therapeutics

Authors

  • Jeremy L. Yap,

    1. Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 Penn Street, Baltimore, MD 21201 (USA), Fax: (+1) 410-706-5017
    Search for more papers by this author
    • These authors contributed equally

  • Dr. Shilpa Worlikar,

    1. Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 Penn Street, Baltimore, MD 21201 (USA), Fax: (+1) 410-706-5017
    Search for more papers by this author
    • These authors contributed equally

  • Prof. Dr. Alexander D. MacKerell Jr.,

    1. Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 Penn Street, Baltimore, MD 21201 (USA), Fax: (+1) 410-706-5017
    Search for more papers by this author
  • Prof. Dr. Paul Shapiro,

    Corresponding author
    1. Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 Penn Street, Baltimore, MD 21201 (USA), Fax: (+1) 410-706-5017
    • Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 Penn Street, Baltimore, MD 21201 (USA), Fax: (+1) 410-706-5017
    Search for more papers by this author
  • Prof. Dr. Steven Fletcher

    Corresponding author
    1. Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 Penn Street, Baltimore, MD 21201 (USA), Fax: (+1) 410-706-5017
    • Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 Penn Street, Baltimore, MD 21201 (USA), Fax: (+1) 410-706-5017
    Search for more papers by this author

Abstract

original image

David and Goliath: Small-molecule inhibitors of the ERK signaling pathway (shown) and their potential as novel antitumor agents are discussed in detail within this Minireview. Specifically, the direct and indirect inhibition of ERK through ATP-competitive and non-ATP-competitive modes of action is highlighted.

Ancillary